Skyrizi
Active substance: risankizumab
INJECTION · RISANKIZUMAB 180 mg/1.2mL
United StatesActive
Marketing holder: AbbVie Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 3
Composition
- RISANKIZUMAB · 180 mg/1.2mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| RU 4 |
|
| EU 1 |
|
Import and control
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-3369-7f6c-899e-d427c75c93d5,01a120c3-58e6-7551-b0a8-9d5e7023719b,01a120c3-ade7-7bf8-a577-6cd399a10e69,01a120c5-e2ae-7876-ba6a-b39232670fcb;count=4 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-f63f-74a2-8fef-2dce2520e4f0,01a1208d-f9c8-7ba8-a51e-c71b673572cb,01a1208f-8568-72db-aa16-4897e08693a3,01a12095-6af3-74ef-b080-dd2761d4752f,01a12095-6b46-7072-bda5-0d8cf47cc7aa;count=6 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 0074-8350
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 0074-8350 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 0074-8350 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 0074-8350 · Verified 2026-10-09 · open in source